FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
vasimigton,	D.O.	200-0

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL								
	OMB Number:	3235-0287							
	Estimated average t	ourden							
- 1	ha nas saanaa.	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Goldenberg Gary					2. Issuer Name and Ticker or Trading Symbol Verrica Pharmaceuticals Inc. [VRCA]								(Ch	eck all appli Direct	cable)	g Pers	on(s) to Iss 10% Ov Other (s	/ner	
(Last) (First) (Middle) C/O VERRICA PHARMACEUTICALS INC. 44 WEST GAY STREET, SUITE 400					3. Date of Earliest Transaction (Month/Day/Year) 03/01/2023									X below) Chief Medical Officer					
(Street) WEST CHESTE	ER PA	A	19380		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)						Lin	ndividual or Joint/Group Filing (Check Applicable s) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S		(Zip)		<u> </u>														
1. Title of Security (Instr. 3) 2. Trai			2. Transa Date (Month/E	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transacti Code (Ins 8)	ion 5,	r. 5)		ed (A) or tr. 3, 4 and	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		3)		7. Nature of Indirect Beneficial Ownership (Instr. 4)				
		•	Table II - I)						uired, Dis , options					Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate, T	Transac Code (I		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisa Expiration Date (Month/Day/Year		of Securities		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				c	Code	v	(A)	(D)	Date Exercisable		iration e	Title	Amount or Number of Shares						
Employee Stock Option (right to buy)	\$7.58	03/01/2023			A		85,000		(1)	02/2	28/2033	Common Stock	85,000	\$0.00	85,000	0	D		

Explanation of Responses:

1. 25% of the total shares subject to the option shall vest on March 1, 2024 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date.

Remarks:

/s/ Mark Ballantyne, Attorney-

03/03/2023

in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.